Literature DB >> 28912189

Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and between MIF gene polymorphisms and disease susceptibility: a meta-analysis.

Sang-Cheol Bae1, Young Ho Lee2.   

Abstract

AIM: To systematically review evidence regarding the relationship between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis (RA), and the association between MIF gene polymorphisms and RA susceptibility.
DESIGN: We performed a meta-analysis on data of serum/plasma MIF levels in patients with RA and in controls, and on associations between the MIF-173 C/G and -794CATT5-8 polymorphisms and RA susceptibility. PATIENTS: Twelve studies, comprising a total of 362 RA cases and 531 controls evaluated for MIF levels, and 2367 RA cases and 2395 controls evaluated for MIF polymorphisms, were included.
RESULTS: MIF levels were significantly higher in the RA group than in the control group (standardised mean difference (95% CI) 0.923 (0.766 to 1.080), p<0.001). Stratification by ethnicity revealed significantly higher MIF levels in the RA group in Caucasian, Asian and Latin American populations. MIF levels were significantly higher in patients with RA, regardless of adjustment, sample size or data type evaluated. RA was identified to be significantly associated with the MIF-173 C allele (OR (95% CI) 1.271 (1.141 to 1.416), p<0.001), as well as with the -794CATT7 allele (OR (95% CI) 1.229 (1.084 to 1.415), p=0.002) and the -794CATT7-MIF-173C haplotype RA (OR (95% CI) 1.433 (1.138 to 1.805), p=0.002).
CONCLUSIONS: Our meta-analyses revealed significantly higher circulating MIF levels in patients with RA, and found evidence of associations between the MIF-173 C/G and -794CATT5-8 polymorphisms and RA susceptibility. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  MIF level; polymorphism; rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28912189     DOI: 10.1136/postgradmedj-2017-134934

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  6 in total

Review 1.  Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Joshua B Bilsborrow; Edward Doherty; Pathricia V Tilstam; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2019-08-20       Impact factor: 6.902

Review 2.  Deep Insight into the Role of MIF in Spondyloarthritis.

Authors:  Brian Wu; Akihiro Nakamura
Journal:  Curr Rheumatol Rep       Date:  2022-07-09       Impact factor: 4.686

3.  Macrophage migration inhibitory factor promoter polymorphisms are associated with disease activity in rheumatoid arthritis patients from Southern Mexico.

Authors:  Guillermo Santoscoy-Ascencio; Christian Johana Baños-Hernández; José Eduardo Navarro-Zarza; Jorge Hernández-Bello; Richard Bucala; Andres López-Quintero; Emmanuel Valdés-Alvarado; Isela Parra-Rojas; Berenice Illades-Aguiar; José Francisco Muñoz-Valle
Journal:  Mol Genet Genomic Med       Date:  2019-11-07       Impact factor: 2.183

4.  Haptenation of Macrophage Migration Inhibitory Factor: A Potential Biomarker for Contact Hypersensitivity.

Authors:  Lorena Ndreu; Samantha Sasse; Ann-Therese Karlberg; Isabella Karlsson
Journal:  Front Toxicol       Date:  2022-04-06

5.  Association Among MIF, IFIH1, and IL6 Gene Polymorphisms and Non-Segmental Vitiligo in a Chinese Han Population.

Authors:  Danfeng Wang; Shuhui Min; Xiao Lin; Guan Jiang
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-10

6.  Macrophage migration inhibitory factor may play a protective role in osteoarthritis.

Authors:  Ming Liu; Zikun Xie; Guang Sun; Liujun Chen; Dake Qi; Hongwei Zhang; Jieying Xiong; Andrew Furey; Proton Rahman; Guanghua Lei; Guangju Zhai
Journal:  Arthritis Res Ther       Date:  2021-02-20       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.